Larimar Therapeutics, Inc. (LRMR) Stock Profile — Insider Trades & Financials

Net Income-$62.5M

EPS$-1.50

Market Cap$528.8M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Carole Ben-Maimon

CEO & Executive Director

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreichâs ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Employees: 71
Headquarters: Bala Cynwyd, Pennsylvania, United States
Website: www.larimartx.com

Peer ComparisonRevenue ($B)

▾

⚡

Core Efficiency

ROE?

-80.04%

ROA?

-42.85%

D/E Ratio?

0.87

📊

Profitability Ratios

Current Ratio?

2.19

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 3, 2026 (in 147 days)

Annual Report (10-K) — Based on filing pattern

Sep 3, 2026

Predicted10-K

Mar 19, 2026

10-KQ4 20252d after period end

Mar 19, 2026

10-KFY 202578d after period end

Nov 5, 2025

10-QQ3 20252d after period end

Aug 14, 2025

10-QQ2 20252d after period end

Apr 30, 2025

10-QQ1 20253d after period end

Mar 24, 2025

10-KQ4 20244d after period end

Mar 24, 2025

10-KFY 202583d after period end

Oct 30, 2024

10-QQ3 20242d after period end

Loading company sections...

Larimar Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness